Frederick Raal to Risk Assessment
This is a "connection" page, showing publications Frederick Raal has written about Risk Assessment.
Connection Strength
0,935
-
Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 07 11; 82(2):171-181.
Score: 0,203
-
The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Cardiovasc J Afr. 2020 Sep/Oct; 31(5):245-251.
Score: 0,166
-
Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. Atherosclerosis. 2018 10; 277:502-507.
Score: 0,146
-
Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord. 2009 Apr; 7(2):83-8.
Score: 0,075
-
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis. 2003 Dec; 171(2):273-9.
Score: 0,052
-
Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol. 2020 06; 17(6):360-377.
Score: 0,040
-
Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 03 15; 19(1):61.
Score: 0,038
-
Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovasc J Afr. 2019 Jan/Feb 23; 30(1):15-23.
Score: 0,037
-
South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). S Afr Med J. 2018 10 26; 108(11b):973-1000.
Score: 0,037
-
The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol. 2017 11; 24(17):1843-1850.
Score: 0,034
-
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar; 35(3):689-99.
Score: 0,028
-
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec; 34(45):3478-90a.
Score: 0,026
-
Postprandial hyperglycemia in urban South African blacks with and without coronary artery disease. Metab Syndr Relat Disord. 2009 Feb; 7(1):23-9.
Score: 0,019
-
Discovering familial hypercholesterolaemia. S Afr Med J. 2008 Apr; 98(4):232.
Score: 0,018
-
The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG). Cardiovasc J Afr. 2008 Mar-Apr; 19(2):88-94.
Score: 0,017